We recently released a list According to Jim Simons' Renaissance Technology In this article, we will look at the location of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), which, according to Jim Simons' Renaissance technology, is in conflict with other best stocks.
Even after his death in 2024, billionaire investor and mathematician Jim Simons is still known as the "Quantum King" of hedge funds due to his New York-based quantitative trading company. After years of studying the financial industry, Simmons realized the untapped potential of using quantitative analysis to capitalize on market inefficiencies. This insight led him to develop a data-driven investment strategy that uses only statistical and mathematical models to analyze market behavior. By identifying subtle non-random patterns in financial data, Quant Genius predicts future stock movements and produces impressive returns.
Although Jim Simons' Secret Medal Hedge Fund is a Renaissance flagship, it has achieved breakthrough results since its inception. During the DOT-COM collapse in the early 2000s and the global financial crisis between 2007 and 2011, the Medal Fund received 56.6% and 74.6% on impressive returns. The fund's annual yield has been 31.5% since its first two years of operation. At the time of his death, Simmons was worth $31.4 billion, thanks to the medal fund and Renaissance market performance that ranked him among the richest people in the world.
Please read also: 10 stocks of billionaire David Einhorn with huge upward potential and Billionaire Michael Platt has great potential.
Renaissance Technologies' computer-driven powerhouse came off to a great start after a stellar performance in 2024. The Renaissance Institutional Diversified Alpha Fund has gained 9.05% as of February, continuing to build on its impressive 2024 return of 15.6%, which was its best since its inception in 2021. Meanwhile, the Renaissance Institutional Equities Fund has had its best start in over ten years, rising in the first two months of 2025, was 11.85%. In addition to using stock index futures and options to help manage risks, both funds can maintain considerable personal stock positions. However, the company warns that it is difficult to quickly relax these huge holdings without affecting market prices.
In this list, we picked stocks from Renaissance Technologies’ 13F portfolio at the end of the fourth quarter of 2024. These stocks are also popular among elite hedge funds.
Why are we interested in stocks that hedge funds to accumulate? The reason is simple: Our research shows that we can beat the market by mimicking the top stocks of the best hedge funds. Our strategy for quarterly newsletters selects 14 small and large stocks every quarter, returning 373.4% since May 2014, beating its benchmark by 218 percentage points (See more details here).
Pharmacists provide patients with specific medications in professional pharmacies.
Renaissance Technology Q4 shares: US$562.6 million
Number of hedge fund holders: 58
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is a global biotech company involved in the discovery and development of small molecule drugs for the treatment of serious diseases including cystic fibrosis.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) reported first-quarter earnings that were almost unconsensus forecasts, with poor sales of its Alyftrek and Journavx drugs. Nevertheless, the company expressed confidence in future growth by raising the lower end of its financial guidance by $100 million.
On May 7, Bernstein analysts reiterated Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)’s $462 target while maintaining its market performance rating. Analyst William Pickering urged investors to exercise patience after Vertex shares fell 10% on May 6. Bernstein's position proposes a cautious approach, and the company highlights the importance of upcoming product launches and clinical trials, thus determining the future trajectory of the company's stock value.
Greenskeeper Asset Management points out the following about Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) Q1 2025 Investor Letter:
“ Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) was our second best performance this quarter, +20.4%. The growing demand for its cystic fibrosis (CF) franchises continues to generate substantial free cash flow. Vertex remains focused on diversifying its portfolio, with two new endorsement therapies recently launched: Alyftrek and Journavx. Alyfrtek is an improvement in VRTX's CF portfolio, providing a one-day dosing regimen that is more convenient for patients. Importantly, it covers 31 other rare CF mutations without previous treatment. Journavx is a non-opioid pain inhibitor for acute pain, as doctors have confidence in their real-world efficacy and advances in VRTX negotiate reimbursement with payers. We believe that Journavx has the potential to become a blockbuster therapy, thus providing patients with significant quality of life improvements. In addition, VRTX is developing treatments for chronic pain that utilize similar mechanisms of action (burning selective sodium channels) to inhibit the spread of pain signals without almost no off-target effects. Success will be good news for shareholders, but more importantly, it provides a strong alternative to opioids and helps deal with the opioid crisis. ”
Overall, VRTX Ranked seventh Our list of the best stocks, according to Jim Simons' Renaissance Technique. Although we acknowledge the potential of VRTX as an investment, our belief is that certain AI stocks have greater hope and can deliver higher returns and conduct them in a shorter time frame. AI stocks have risen since the beginning of 2025, while popular AI stocks have lost about 25%. If you are looking for AI stocks that are more promising than VRTX but have less than 5 times its earnings, check out our report The cheapest AI stock.
Read the next article: Buy 20 Best AI Stocks Now and According to the billionaire, there are now 30 best stocks.
Disclosure: None. This article was originally published in Inside monkey.